1
|
Trucas M, Kowalik MA, Boi M, Serra MP, Perra A, Quartu M. The density of hepatic autonomic innervation differs between compensatory and direct hyperplasia rat models. J Peripher Nerv Syst 2023; 28:98-107. [PMID: 36371610 DOI: 10.1111/jns.12521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 10/23/2022] [Accepted: 11/07/2022] [Indexed: 11/15/2022]
Abstract
To contribute to the knowledge of the autonomic innervation in liver regeneration, here we investigate the distribution of tyrosine hydroxylase (TH)- and choline acetyltransferase (ChAT)-like immunoreactive (LI) nerve fibers, to indicate noradrenergic and cholinergic nerves, respectively, in rats under different conditions of liver damage and repair. By immunohistochemistry and assessment of nerve fiber density, three models of induced hepatic regeneration were examined: the carbon tetrachloride (CCl4 ) intoxication, with two treatment periods of 14 weeks and 18 weeks; the partial hepatectomy (PH); the thyroid hormone (T3) treatment. TH- and ChAT-LI nerve fibers were detectable mostly in the portal spaces, the TH-LI ones occurring only around blood vessels while the ChAT-LI nerve fibers were also associated with secretory ducts. The density of TH-like immunoreactivity in the portal areas decreased after the CCl4 14 weeks treatment and PH and increased after T3. By contrast, ChAT-LI nerve fibers appeared particularly abundant around the neoductal elements in the CCl4 rats and were rare to absent in the PH and T3-treated groups. The ChAT-LI nerve fiber density within the portal areas revealed an increase in the CCl4 -treated rats while showing no change in the PH and T3-treated rats. The changes in the density of perivascular TH- and ChAT-containing nerve fibers suggest a finely tuned autonomic modulation of hepatic blood flow depending on the type of subacute/chronic induced hyperplasia, while the characteristic occurrence of the periductal cholinergic innervation after the CCl4 treatment implies a selective parasympathetic role in regulating the physiopathological regenerative potential of the rat liver.
Collapse
Affiliation(s)
- Marcello Trucas
- Department of Biomedical Sciences, Section of Cytomorphology, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy.,Department of Biomedical Sciences, Section of Pathology, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy
| | - Marta Anna Kowalik
- Department of Biomedical Sciences, Section of Pathology, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy
| | - Marianna Boi
- Department of Biomedical Sciences, Section of Cytomorphology, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy
| | - Maria Pina Serra
- Department of Biomedical Sciences, Section of Cytomorphology, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy
| | - Andrea Perra
- Department of Biomedical Sciences, Section of Pathology, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy
| | - Marina Quartu
- Department of Biomedical Sciences, Section of Cytomorphology, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy
| |
Collapse
|
2
|
Key genes in the liver fibrosis process are mined based on single-cell transcriptomics. Biochem Biophys Res Commun 2022; 598:131-137. [DOI: 10.1016/j.bbrc.2022.01.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 01/24/2022] [Indexed: 11/23/2022]
|
3
|
Yan L, Zhang X, Fu J, Liu Q, Lei X, Cao Z, Zhang J, Shao Y, Tong Q, Qin W, Liu X, Liu C, Liu Z, Li Z, Lu J, Xu X. Inhibition of the transient receptor potential vanilloid 3 channel attenuates carbon tetrachloride-induced hepatic fibrosis. Biochem Biophys Res Commun 2021; 558:86-93. [PMID: 33906111 DOI: 10.1016/j.bbrc.2021.04.065] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 04/16/2021] [Indexed: 02/07/2023]
Abstract
Transient receptor potential vanilloid 3 (TRPV3) is a member of the TRP superfamily. Previous studies have demonstrated that TRPV3 is associated with myocardial fibrosis. However, the role of TRPV3 in hepatic fibrosis and its underlying mechanisms are still unclear. This study aimed to elucidate the underlying effects of TRPV3 on hepatic fibrosis at multiple biological levels. First, immunohistochemical staining was performed to examine TRPV3 expression in human hepatic cirrhosis tissues. Then, we established a CCl4-induced hepatic fibrosis mouse model. The TRPV3 selective agonist drofenine and its inhibitor, forsythoside B, were intraperitoneally injected to investigate the relationship between TRPV3 and liver fibrosis progression. Finally, in vitro studies were performed using hepatic stellate cells (HSCs) to discover the potential molecular biological mechanisms. Immunohistochemistry revealed TRPV3 overexpression in liver cirrhosis. In the liver fibrosis groups, TRPV3 inhibitor treatment significantly reduced liver fibrosis, while TRPV3 agonist exacerbated its progression. In HSCs, knocking down TRPV3 with siRNA impaired DNA synthesis and cell proliferation and increased cell apoptosis. Furthermore, we found that knockdown of TRPV3 could reduce the lectin like oxidized lowdensity lipoprotein receptor-1 (LOX-1) protein levels. Our research suggests that lower expression or functional levels of TRPV3 can ameliorate the inflammatory response and fibrotic tissue proliferation.
Collapse
Affiliation(s)
- Likun Yan
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Xiao Zhang
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Jie Fu
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Qiang Liu
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Xiaohua Lei
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Zhenyu Cao
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Ju Zhang
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Yaoli Shao
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Qing Tong
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Wei Qin
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Xinxu Liu
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Chun Liu
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Zhiqiang Liu
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Zhenghao Li
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Jueliang Lu
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
| | - Xundi Xu
- Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China; Department of General Surgery. Pinghu Hospital, Health Science Center, Shenzhen University, Shenzhen, 518116, China.
| |
Collapse
|
4
|
Loftis JM, Valerio J, Taylor J, Huang E, Hudson R, Taylor-Young P, Chang M, Ho SB, Dieperink E, Miranda JL, Hauser P. S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder. Alcohol Clin Exp Res 2018; 42:10.1111/acer.13796. [PMID: 29953169 PMCID: PMC6310679 DOI: 10.1111/acer.13796] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Accepted: 05/15/2018] [Indexed: 12/24/2022]
Abstract
BACKGROUND Hepatitis C virus (HCV) infection and alcohol use disorder (AUD) both adversely affect the immune system resulting in alterations in immune cell signaling and inflammatory processes. The aim of this study was to investigate how comorbid AUD contributes to abnormalities in inflammatory mediators and psychiatric impairments in adults with HCV. METHODS Alcohol use, mood, and inflammatory factors were evaluated at 3 time points (baseline, week 4, and week 12) in Veterans with HCV, with (n = 42) and without (n = 13) comorbid AUD. Peripheral indices of immune activation, blood-brain barrier (BBB) damage (S100 calcium-binding protein B [S100B]), liver function, and viral load were measured using immunoassays and polymerase chain reaction assays. RESULTS Comorbid AUD was associated with increased symptoms of depression and anxiety, elevated levels of liver enzymes, and altered expression of inflammatory factors. Alcohol consumption was positively correlated with the severity of psychiatric symptoms. Univariate analysis identified significant group differences in interleukin (IL)-8 (p = 0.006), IL-10 (p = 0.03), and S100B (p = 0.048), with increased levels in participants with AUD, which persisted over time despite reductions in alcohol use and no significant change in HCV viral load. Statistically significant effects of study group or time were not found for the other immune factors assessed. Exploratory receiver operating characteristic curve analysis evaluated the ability of IL-8, IL-10, and S100B to differentiate between levels of alcohol consumption and generated biomarker cutoff values used to identify low risk and unhealthy alcohol use groups. CONCLUSIONS These results demonstrate that HCV and comorbid AUD are associated with greater psychiatric impairments, potentially resulting from increased inflammation, dysregulated cytokine expression, and compromised BBB function. Alcohol-induced BBB damage may increase the risk of neuropathological consequences within the context of chronic HCV infection.
Collapse
Affiliation(s)
- Jennifer M. Loftis
- Research & Development Service, VA Portland Health Care System, Portland, OR, USA
- Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA
| | - Juno Valerio
- Research & Development Service, VA Portland Health Care System, Portland, OR, USA
| | - Jonathan Taylor
- Research & Development Service, VA Portland Health Care System, Portland, OR, USA
- Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA
| | - Elaine Huang
- Research & Development Service, VA Portland Health Care System, Portland, OR, USA
- Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA
| | - Rebekah Hudson
- Research & Development Service, VA Portland Health Care System, Portland, OR, USA
| | - Patricia Taylor-Young
- Nursing Research Department, VA Portland Health Care System, Portland, OR, USA
- School of Nursing, Oregon Health & Science University, Portland, OR, USA
| | - Michael Chang
- Gastroenterology, VA Portland Health Care System, Portland, OR, USA
- Internal Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Samuel B. Ho
- VA San Diego Healthcare System, San Diego, CA, USA
- Department of Medicine, University of California San Diego, San Diego, CA, USA
| | - Eric Dieperink
- Minneapolis VA Healthcare System, Minneapolis, MN, USA
- Department of Psychiatry, University of Minnesota School of Medicine, Minneapolis, MN, USA
| | - Juan Luis Miranda
- VA Long Beach Health Care System, 5901 E 7th St, Long Beach, CA, USA
| | - Peter Hauser
- VA Long Beach Health Care System, 5901 E 7th St, Long Beach, CA, USA
- Department of Psychiatry and Human Behavior, University of California-Irvine, Irvine, CA, USA
- Department of Psychiatry, University of California San Diego, San Diego, CA, USA
| |
Collapse
|
5
|
Ramzy MM, Abdelghany HM, Zenhom NM, El-Tahawy NF. Effect of histone deacetylase inhibitor on epithelial-mesenchymal transition of liver fibrosis. IUBMB Life 2018; 70:511-518. [DOI: 10.1002/iub.1742] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 03/02/2018] [Accepted: 03/05/2018] [Indexed: 01/04/2023]
Affiliation(s)
- Maggie M. Ramzy
- Department of Biochemistry, Faculty of Medicine; Minia University; Egypt
| | - Hend M Abdelghany
- Department of Biochemistry, Faculty of Medicine; Minia University; Egypt
| | - Nagwa M. Zenhom
- Department of Biochemistry, Faculty of Medicine; Minia University; Egypt
| | - Nashwa F. El-Tahawy
- Department of Histology and Cell Biology, Faculty of Medicine; Minia University; Egypt
| |
Collapse
|
6
|
Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med 2017; 32:213-228. [PMID: 28171717 PMCID: PMC5339475 DOI: 10.3904/kjim.2016.268] [Citation(s) in RCA: 88] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Accepted: 12/23/2016] [Indexed: 02/06/2023] Open
Abstract
In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.
Collapse
Affiliation(s)
| | - Hyung Joon Yim
- Correspondence to Hyung Joon Yim, M.D. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, 123 Jeokgeum-ro, Danwon-gu, Ansan 15355, Korea Tel: +82-31-412-6565 Fax: +82-31-412-5582 E-mail:
| |
Collapse
|